Team

Management Team

Pavel Raifeld

Chief Executive Officer

Pavel Raifeld, CFA, joined Innoviva as Chief Executive Officer in May 2020. Prior to that, Mr. Raifeld served on the investment team at Sarissa Capital Management LP, an investment management firm focused on improving strategies of companies to enhance shareholder value. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey & Company and The Boston Consulting Group. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.

Steve Basso

Chief Financial Officer Mr. Basso brings more than 30 years of experience of financial leadership, primarily in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served as the Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics and has held a variety of financial leadership positions at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer. He received a BS in business from Providence College and an MBA from Boston College.

Marianne Zhen, CPA

Chief Accounting Officer

Marianne Zhen joined Innoviva in October 2014. Prior to joining Innoviva, Ms. Zhen served as the Corporate Controller at Steelwedge Software Inc. from 2012 to 2014, Intelmate from 2011 to 2012 and Model N, Inc. from 2007 to 2011. Previously, Ms. Zhen served as a member of the board of directors of CalCPA Peninsula Silicon Valley Chapter. Ms. Zhen earned a Bachelor of Science degree in Business Administration with a concentration in Accounting from San Francisco State University. She is a member of the American Institute of Certified Public Accountants (AICPA) and a member of California Society of Certified Public Accountants (CalCPA).

David Altarac, M.D.

Chief Medical Officer, IST Dr. Altarac is an infectious diseases physician and pharmaceutical executive with more than 20 years’ experience leading clinical and regulatory functions. He previously served as the Chief Medical Officer of Entasis Therapeutics and held leadership positions at Shire Pharmaceuticals, NeoStem, Inc., and Merck & Co. in therapeutic areas including infectious diseases, oncology, ophthalmology, inflammation, and rare diseases. Dr. Altarac holds an M.D. degree from New York Medical College, a Master of Public Administration (M.P.A.) degree from New York University, and a B.A. in Chemistry from the State University of New York at Binghamton, NY.

Patricia Drake

Chief Commercial Officer, IST Ms. Drake is a highly accomplished life science professional with over thirty years of extensive U.S. and international experience managing commercial portfolios. Her strong leadership background encompasses commercial strategy, marketing, market access, sales and operations. Prior to joining Innoviva Specialty Therapeutics, Ms. Drake served as the SVP and Chief Commercial Officer at Trevena, Inc. During her tenure at Merck & Co. Inc., she successfully led commercial organizations across diverse global markets and product portfolios, which included antiviral, oncology, antifungal, and antibiotic products and multiple global business units spanning North and South America and the Nordics. Ms. Drake holds a Bachelor of Science from Wichita State University and attended the Harvard Business School Emerging Leaders Program and Executive Program in Leadership and Strategy.

Board of Directors

Jules Haimovitz

Mr. Haimovitz has served as a member of our Board of Directors since February 2018, and as Chairman of the Board of Directors since May 2026. He is currently Chair of the Audit Committee, Chair of our Compensation Committee, and a member of the Nominating/Corporate Governance Committee.

Mr. Haimovitz is currently President of Haimovitz Consulting, Inc. He also serves on the Board of Directors at Armata Pharmaceuticals, Inc. He previously served as a member of the board of directors of Ariad Pharmaceuticals, where he was also a member of the audit committee; Dial Global, Inc., where he was also member of the audit committee; and Imclone Pharmaceuticals, where he served as chairperson of the audit committee. Mr. Haimovitz has also served as Chief Executive Officer or Chief Operating Officer of the following companies: Spelling Entertainment, Inc., King World Productions and VJN, Inc. Mr. Haimovitz holds a B.S. (1971) and M.A. (1974) degree in Mathematics from Brooklyn College.

Chair of the Audit Committee

Chair of the Compensation Committee

Member of the Nominating/Corporate Governance Committee

Josephine Linden

Josephine Linden has served as a member of our board of directors since May 2026. She is Founder and CEO of Linden Global Strategies, a wealth management advisory firm and multi-family office. She retired from Goldman Sachs as a partner and managing director in 2009, after being with the firm for over twenty-five years.

Josephine serves on public, non-profit, and family boards. She is the Chairman of the Board of Lands’ End, a Board Member of E&P Financial Group, and a Founding Board Member of Global Australians. Josephine was Adjunct Professor at the Business School of Columbia University, where she taught a class in wealth management and currently teaches and moderates ad hoc sessions. Josephine serves on the Investment Committees of the Freedom Together Foundation, the Collegiate School, and the Asia Society. She is also Trustee and Treasurer Emeritus of the Collegiate School, and a Global Trustee of the Asia Society.

Josephine is a longtime member of the Council on Foreign Relations and the Trilateral Commission. In 2022, Josephine was appointed an Honorary Member of the Order of Australia (AM). Josephine received an MBA from the University of Chicago and a BA from the University of Sydney.

Pavel Raifeld

Chief Executive Officer

Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey & Company and The Boston Consulting Group. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.

Sarah J. Schlesinger, M.D.

Sarah J. Schlesinger, M.D., has served as a member of our Board of Directors since February 2018. She is Chair of the Nominating/Corporate Governance Committee and a member of the Compensation Committee and the Audit Committee.

Dr. Schlesinger is an Associate Professor of Clinical Investigation at Rockefeller University and Senior Attending Physician at Rockefeller University Hospital. Dr. Schlesinger led the Dendritic Cell section of the Division of Retrovirology at the Walter Reed Army Institute of Research and was also a member of the Division of Infectious and Parasitic Disease Pathology at the Armed Forces Institute of Pathology from 1994 to 2002.

In 2002, Dr. Schlesinger rejoined Rockefeller University and began working with the International AIDS Vaccine Initiative as a Scientist in Vaccine Research and Design. Dr. Schlesinger has been a member of Rockefeller University Hospital’s Institutional Review Board (“IRB”) (Ethics Committee) since 2003 and previously served as IRB’s vice-chairperson. In 2017 she assumed the position of chairperson of the IRB. She is currently the director of the education and training programs at Rockefeller University Center for Clinical and Translational Science and serves on the Medical Staff Executive Committee of Rockefeller University Hospital. Dr. Schlesinger currently serves on the board of directors at Armata Pharmaceuticals, Inc. and the board of three non-profit organizations: the AIDS Vaccines Advocacy Coalition, Global Viral and The Hastings Center, the pre-eminent center for the study of bioethics. Dr. Schlesinger served as an independent corporate director of Ariad Pharmaceuticals from 2013 until its sale to Takeda Pharmaceutical Company Limited in 2017. Dr. Schlesinger has a B.A. from Wellesley College and a M.D. from Rush Medical College in Chicago, Illinois.

Chair of the Nominating/Corporate Governance Committee

Member of the Compensation Committee

Member of the Audit Committee